Computed.
Synthesized.
Validated.

We're building silicon-to-cell integration that collapses traditional discovery timelines

Supported by:

YURiA-PHARMKSEMESIP_office
YURiA-PHARMKSEMESIP_office

Our Features

FAZENA leverages quantum chemistry and AI to design next-generation therapeutics through the first end-to-end in silico-to-cell platform. We transform computational predictions into experimentally validated therapeutic candidates. While our full pipeline is under construction, we're already accelerating pharma R&D through specialized services and our AI-powered SaaS platform.

Projects in Development

We are actively advancing three strategic initiatives: developing novel therapeutics for neurodegenerative diseases, cancer, and diabetes; building integrated in silico and in vivo platforms to power our unified drug discovery pipeline; and partnering with pharmaceutical companies on targeted research projects.

Drug CandidatesNovel therapeutics addressing high unmet medical needs in neurodegeneration, oncology, and metabolic disorders
Alzheimer's disease ABCA7-targetingLearn more →
Target ID
Hit Discovery
Lead Opt
Preclinical
Phase I
Platform DevelopmentConnecting computational design tools with experimental validation systems
RNA HunterLearn more →
Concept
Prototype
Validation
Optimization
Launch
CycloSpaceLearn more →
Concept
Prototype
Validation
Optimization
Launch
Building PartnershipsStrategic collaborations with pharmaceutical companies and research institutions
YURiA-PHARM
Outreach
Evaluation
Negotiation
Contract
Active

Our Innovation

An innovative approach in the design of the ABCA7 modulator was the use of modern tools that utilize transformers and deep neural networks to obtain the structures of mutant forms of this transporter protein. We achieved high-quality structures, which allowed us to further use this for molecular docking and dynamics, calculating binding and dissociation constants. At this stage, we are optimizing leads and expanding our understanding of what other genetic features and relationships between mutations of this protein and drug development may exist. We have now begun work on publishing a series of articles in scientific journals. Our work was highly praised at the Neuro Impact Challenge, where we took first place.

Molecule Animation
v1.0.0HTVS
100%Druggability
-20 kcal/moldG
Background shape

RNA Hunter

Obtaining the spatial structure of non-coding RNAs and finding therapeutic small molecules for this target. Modelling in intracellular conditions, molecular dynamics, refinement of the lead molecule using QM/MM methods, calculation of free binding energy and other parameters. The platform is not limited by target length.

RNA Hunter platform screenshot
Macrocycle Design
v1.0.0Version
QM+AIEngine
-40 kcal/molRosetta ddG

CycloSpace

In development

Creation of rigid, structurally defined macrocycles with optimized binding, stability, and permeability through the use of a library of rationally selected non-canonical amino acids.

Design based on both structure-dependent and sequence-oriented approaches

Development of molecular glues that promote target degradation or enhanced interaction with PPI partners

Application to highly complex undruggable targets

Unique technical solutions for tissue-selective peptides

Services

Comprehensive toolkit for computational drug design and biomolecular engineering.

HTVS

Virtual screening of small molecules against your target (protein, RNA, DNA).

In silico research

Research into the molecular mechanism of action of your small molecule.

Reprofilization of drugs

Repurposing of known active pharmaceutical ingredients

Structural bioinformatics & CADD

Docking and molecular dynamics of the target-ligand complex (which may be protein-protein, protein-nucleic acid, or protein-peptide interactions).

Biotechnology

Design of replacement therapy proteins, redesign of proteins with a known active site.

CRISPR/Cas technologies

Design gRNAs for your target, structural binding verification.

FAZENA Team

Meet the minds reshaping drug discovery — specialists in bioinformatics, biochemistry, biotechnology, and synthetic biology working together to bring novel therapeutics from concept to reality.

Yehor Franchuk

Yehor Franchuk

CEO & Co-Founder

Anatolii Zbrotskyi

Anatolii Zbrotskyi

CSO & Co-Founder

Dmytro Alexandrovych

Dmytro Alexandrovych

CFO & Co-Founder

Yevhenii Zhuromskyi

Yevhenii Zhuromskyi

CRO & Co-Founder

Yuliia Naum

Yuliia Naum

Wet Lab Scientist

Arsenii Bahdasarov

Arsenii Bahdasarov

Software Engineer

Oksana Kolisnyk

Oksana Kolisnyk

ML Engineer

Join Our Team

Help us redefine drug discovery

Latest Publications

Explore our most recent research papers, articles, and insights on the future of AI-driven drug discovery.

Discovery of a Druggable Ligand-Binding Site in Phospholipid-Transporting ATPase ABCA7
Coming Soon
ResearchComing Soon

Discovery of a Druggable Ligand-Binding Site in Phospholipid-Transporting ATPase ABCA7

Rational in silico design of a peptide binder that inhibits CERT1
ResearchOctober 23, 2025

Rational in silico design of a peptide binder that inhibits CERT1

Rational in silico redesign of the CERT1 protein
ResearchOctober 23, 2025

Rational in silico redesign of the CERT1 protein

Partner with us!

Join forces with FAZENA to accelerate drug discovery. Whether you're a research institution, pharmaceutical company, or biotech venture, let's collaborate to transform computational predictions into validated therapeutics.

Start a Conversation